CA2845994C - Method for detecting nucleosomes containing histone variants - Google Patents

Method for detecting nucleosomes containing histone variants Download PDF

Info

Publication number
CA2845994C
CA2845994C CA2845994A CA2845994A CA2845994C CA 2845994 C CA2845994 C CA 2845994C CA 2845994 A CA2845994 A CA 2845994A CA 2845994 A CA2845994 A CA 2845994A CA 2845994 C CA2845994 C CA 2845994C
Authority
CA
Canada
Prior art keywords
histone
nucleosomes
nucleosome
cancer
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2845994A
Other languages
English (en)
French (fr)
Other versions
CA2845994A1 (en
Inventor
Jacob Vincent Micallef
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belgian Volition SPRL
Original Assignee
Belgian Volition SPRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Belgian Volition SPRL filed Critical Belgian Volition SPRL
Publication of CA2845994A1 publication Critical patent/CA2845994A1/en
Application granted granted Critical
Publication of CA2845994C publication Critical patent/CA2845994C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
CA2845994A 2011-09-01 2012-08-31 Method for detecting nucleosomes containing histone variants Active CA2845994C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161530304P 2011-09-01 2011-09-01
GBGB1115098.4A GB201115098D0 (en) 2011-09-01 2011-09-01 Method for detecting nucleosomes containing histone variants
US61/530,304 2011-09-01
GB1115098.4 2011-09-01
PCT/GB2012/052131 WO2013030579A1 (en) 2011-09-01 2012-08-31 Method for detecting nucleosomes containing histone variants

Publications (2)

Publication Number Publication Date
CA2845994A1 CA2845994A1 (en) 2013-03-07
CA2845994C true CA2845994C (en) 2020-10-13

Family

ID=44882049

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2845994A Active CA2845994C (en) 2011-09-01 2012-08-31 Method for detecting nucleosomes containing histone variants

Country Status (20)

Country Link
US (5) US9400276B2 (enExample)
EP (2) EP3301449B1 (enExample)
JP (2) JP2014529405A (enExample)
KR (1) KR102130855B1 (enExample)
CN (2) CN108107215A (enExample)
AU (1) AU2012300643B2 (enExample)
BR (1) BR112014004584B1 (enExample)
CA (1) CA2845994C (enExample)
DK (1) DK2751569T3 (enExample)
ES (2) ES2662380T3 (enExample)
GB (1) GB201115098D0 (enExample)
HR (1) HRP20180362T1 (enExample)
HU (1) HUE038517T2 (enExample)
MX (1) MX349561B (enExample)
PL (1) PL2751569T3 (enExample)
PT (1) PT2751569T (enExample)
RU (2) RU2716494C2 (enExample)
SG (2) SG10201601168QA (enExample)
WO (1) WO2013030579A1 (enExample)
ZA (1) ZA201401296B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
EP4155401A1 (en) 2012-03-02 2023-03-29 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP2859139B1 (en) 2012-06-06 2018-08-01 The Trustees Of Princeton University Dna barcoding of designer mononucleosome and chromatin array libraries for the profiling of chromatin readers, writers, erasers, and modulators thereof
EP3597774A1 (en) 2013-03-13 2020-01-22 Sequenom, Inc. Primers for dna methylation analysis
WO2015138774A1 (en) 2014-03-13 2015-09-17 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
SG11201702978VA (en) * 2014-10-29 2017-05-30 Belgian Volition Sprl Method for the enrichment of circulating tumor dna
EP3256858B1 (en) * 2015-02-10 2020-03-25 B.R.A.H.M.S GmbH Histone h4 peptide as a biomarker
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201518665D0 (en) 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201518674D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
GB201612815D0 (en) * 2016-07-25 2016-09-07 Belgian Volition Sa Novel combination test
TWI726009B (zh) * 2016-11-28 2021-05-01 比利時商比利時意志有限公司 用親和純化法分析生物樣品中源自腫瘤之無細胞核小體、分離生物樣品中純化之腫瘤dna、檢測生物樣品中源自腫瘤之核小體表觀遺傳表位或在動物或人類受試者中檢測癌症之方法或包括組蛋白h1結合劑之套組之用途
KR102993694B1 (ko) 2016-12-09 2026-07-22 더 브로드 인스티튜트, 인코퍼레이티드 Crispr 이펙터 시스템 기반 진단
CN111108220B (zh) 2017-03-15 2024-11-19 博德研究所 用于病毒检测的基于crispr效应系统的诊断
GB201721569D0 (en) 2017-12-21 2018-02-07 Belgian Volition Sprl Method for the detection and treatment of colorectal adenomas
KR102857066B1 (ko) 2018-01-29 2025-09-08 더 브로드 인스티튜트, 인코퍼레이티드 Crispr 이펙터 시스템 기반 진단
CN111918971B (zh) 2018-03-01 2024-09-03 埃皮塞弗公司 利用化学确定的重组核小体定量核小体修饰
CA3302676A1 (en) 2018-04-02 2026-05-13 Grail, Inc. Methylation markers and targeted methylation probe panels
EP3856903A4 (en) 2018-09-27 2022-07-27 Grail, LLC METHYLATION MARKER AND TARGETED METHYLATION PROBE PANEL
GB201818965D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Method for the detection of colorectal cancer
GB201818963D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Methof for the detection of prostate cancer
GB201906199D0 (en) 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
GB201906201D0 (en) 2019-05-02 2019-06-19 Belgian Voltion Sprl Method for the detection of protate cancer
JP2022545821A (ja) 2019-08-27 2022-10-31 ベルジアン ボリション エスアールエル 循環ヌクレオソームを単離する方法
GB201912251D0 (en) 2019-08-27 2019-10-09 Belgian Volition Sprl Method of isolating circulating nucleosomes
US20230003735A1 (en) 2019-12-02 2023-01-05 Belgian Volition Srl Use of cell free nucleosomes as biomarkers
BR112022018792A2 (pt) 2020-03-20 2022-11-01 Belgian Volition Srl Método de triagem usando níveis de nucleossomos livres de células
US12636417B2 (en) 2020-09-21 2026-05-26 Belgian Volition Srl Device for inline monitoring of free nucleosomes in blood
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202238132A (zh) 2020-12-08 2022-10-01 比利時商比利時意志有限公司 多發性硬化症之診斷方法
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
TW202242130A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242146A (zh) 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
GB202108185D0 (en) 2021-06-08 2021-07-21 Belgian Volition Sprl Standardisation of nucleosome assays using biologically derived calibrants
GB202108452D0 (en) 2021-06-14 2021-07-28 Belgian Volition Sprl Triaging method using cell free nucleosome levels
WO2023073179A1 (en) 2021-10-29 2023-05-04 Belgian Volition Srl Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
US20250197944A1 (en) 2022-03-11 2025-06-19 Belgian Volition Srl Differential diagnosis method
GB202205212D0 (en) 2022-04-08 2022-05-25 Belgian Volition Sprl Method for transplant organ health assessment
WO2024042208A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for the detection of dementia
EP4577833A1 (en) 2022-08-25 2025-07-02 Belgian Volition SRL Method for measuring cell free chromatin
US20260028678A1 (en) 2022-12-19 2026-01-29 Belgian Volition Srl Assessment of biological samples for nucleic acid analysis
EP4639173A1 (en) 2022-12-19 2025-10-29 Belgian Volition SRL Calibration
GB202300607D0 (en) 2023-01-16 2023-03-01 Belgian Volition Srl Proteins and methods for isolating circulating nucleosomes
GB202303562D0 (en) 2023-03-10 2023-04-26 Belgian Volition Sprl Sample collection for liquid biopsy
EP4695610A1 (en) 2023-04-14 2026-02-18 Belgian Volition SRL Diagnosis method using cell free nucleosome levels
WO2024223947A1 (en) 2023-04-28 2024-10-31 Belgian Volition Srl Use of cell free nucleosomes as biomarkers of carcinomas
GB202307768D0 (en) 2023-05-24 2023-07-05 Belgian Volition Srl Use of cell free nucleosomes as biomarkers
GB202310137D0 (en) 2023-07-03 2023-08-16 Belgian Volition Srl Method for the detection of cancer
EP4743782A1 (en) 2023-07-13 2026-05-20 Belgian Volition SRL METHOD FOR DETECTING THE POTENTIAL OF A BODY FLUID SAMPLE FOR PRODUCING EXTRACELLULAR TRAPS
EP4781203A1 (en) 2023-09-19 2026-07-29 Belgian Volition SRL Lateral flow test device
WO2025093747A1 (en) 2023-11-02 2025-05-08 Belgian Volition Srl Novel rapid high-throughput method of netosis induction and inhibition with physiologically relevant molecules
WO2025181348A1 (en) 2024-03-01 2025-09-04 Belgian Volition Srl Method for determining the origin of circulating dna
WO2025253002A1 (en) 2024-06-07 2025-12-11 Belgian Volition Srl Sample collection for liquid biopsy
WO2026052765A1 (en) 2024-09-05 2026-03-12 Belgian Volition Srl Method using nucleosome levels

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411975A4 (en) 2001-07-03 2005-04-27 Univ Virginia METHYLATION OF HISTON H4 AT ARGININE 3
DE10207735A1 (de) * 2002-02-15 2003-08-28 Euroimmun Gmbh Verfahren zur Herstellung einer Nukleosomen-Präparation und deren Verwendung zur in vitro-Diagnose von Lupus erythematodes disseminatus (LED)
AU2003216291A1 (en) 2002-02-20 2003-09-09 Chroma Therapeutics Ltd. A non-invasive diagnostic test utilizing histone modification markers
GB0319376D0 (en) * 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
WO2005040814A1 (en) * 2003-10-14 2005-05-06 Cancer Research Technology Limited Methods and means of cancer detection by histone modification
WO2007017065A2 (en) * 2005-07-27 2007-02-15 Oncomethylome Sciences Sa Angiogenesis inhibition based upon icam 1 or junb expression levels
WO2007032876A2 (en) * 2005-09-09 2007-03-22 University Of Iowa Research Foundation Biomarkers associated with age-related macular degeneration
US20110312897A1 (en) * 2008-09-17 2011-12-22 The Rockefeller University Cathepsin l proteolytically processes histone h3 during mouse embryonic stem cell differentiation
EP2270510A1 (en) * 2009-07-02 2011-01-05 EMBL (European Molecular Biology Laboratory) Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants

Also Published As

Publication number Publication date
US20200341006A1 (en) 2020-10-29
RU2014112348A (ru) 2015-10-10
ZA201401296B (en) 2014-12-23
GB201115098D0 (en) 2011-10-19
HK1199758A1 (en) 2015-07-17
JP2017215338A (ja) 2017-12-07
RU2018101257A3 (enExample) 2019-02-21
EP3301449B1 (en) 2023-08-09
EP3301449C0 (en) 2023-08-09
EP2751569B1 (en) 2017-12-27
PT2751569T (pt) 2018-03-28
ES2955475T3 (es) 2023-12-01
US9400276B2 (en) 2016-07-26
DK2751569T3 (en) 2018-03-12
EP2751569A1 (en) 2014-07-09
SG11201400202SA (en) 2014-03-28
JP2014529405A (ja) 2014-11-13
US20140206014A1 (en) 2014-07-24
RU2716494C2 (ru) 2020-03-12
BR112014004584A2 (pt) 2017-05-16
WO2013030579A1 (en) 2013-03-07
EP3301449A1 (en) 2018-04-04
CN108107215A (zh) 2018-06-01
AU2012300643A1 (en) 2014-03-06
ES2662380T3 (es) 2018-04-06
BR112014004584B1 (pt) 2021-07-06
SG10201601168QA (en) 2016-03-30
KR20140078638A (ko) 2014-06-25
MX349561B (es) 2017-08-02
CN104053993A (zh) 2014-09-17
PL2751569T3 (pl) 2018-06-29
US10184945B2 (en) 2019-01-22
HUE038517T2 (hu) 2018-10-29
KR102130855B1 (ko) 2020-07-09
AU2012300643B2 (en) 2017-06-15
JP6494703B2 (ja) 2019-04-03
RU2018101257A (ru) 2019-02-21
HRP20180362T1 (hr) 2018-06-01
US20190120853A1 (en) 2019-04-25
US20230116530A1 (en) 2023-04-13
CA2845994A1 (en) 2013-03-07
MX2014002444A (es) 2014-10-23
HK1253354A1 (en) 2019-06-14
US20160299152A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
US20230116530A1 (en) Method for detecting nucleosomes containing histone variants
US20200347435A1 (en) Method for detecting nucleosomes containing nucleotides
US9222937B2 (en) Method for detecting nucleosomes
US20170003296A1 (en) Method for detecting histone modifications in nucleosomes
HK40008468A (en) Method for detecting nucleosomes containing nucleotides
HK1253354B (en) Method for detecting nucleosomes containing histone variants
HK1199758B (en) Method for detecting nucleosomes containing histone variants
HK1199760B (en) Method for detecting nucleosomes containing nucleotides
HK1199761B (en) Method for detecting nucleosomes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170804

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250821

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250821